Moderna Sales Climb on Strong Demand for Covid-19 Vaccine

Moderna Inc.

MRNA -0.43%

sales rose 9% in the second quarter as demand for its Covid-19 vaccine remained strong.

The Cambridge, Mass.-based biotechnology company’s revenue came in at $4.75 billion in the period ended June 30, topping Wall Street analyst expectations, driven almost entirely by sales of its messenger RNA-based vaccine, branded as Spikevax.

At the same time, Moderna’s…

Read More